Dilution of Share Value Through Exercise of Stock Acquisition Rights
First written in FY2016. 28 of 30 entries say "Worsened", first in FY2017-Q2. Latest entry: 2026-09-24.
The whole theme swung hardest in 2017: 37 of 68 companies on the "Worse" side.
- FY2026WorsenedAnnual report
「Balance of unexercised rights at period-end: 817,500 shares / Balance exercisable at period-end: 371,000 shares」
A new eighth series of stock acquisition rights covering 446,500 shares was granted, bringing the period-end balance of unexercised rights, including the exercise and expiration of existing rights, to 817,500 shares. Additional potential shares that could result in dilution have been added. - 2026-05-14WorsenedEarnings presentation
「Number issued: 4,465 units (equivalent to 446,500 shares)」
The number of shares that could potentially result in future dilution through the issuance of paid stock options was disclosed. - FY2026-H1WorsenedAnnual report
「1 April 2025–30 September 2025 (Note) 23,600 23,118,900 4 2,222 4 2,366 (Note) Increase due to the exercise of stock acquisition rights.」
The number of shares issued increased by 23,600 during the current interim consolidated accounting period through the exercise of stock acquisition rights, and the number of shares that could result in dilution of shareholder value continued to increase. - FY2025WorsenedAnnual report
「1 April 2024–31 March 2025 (Note 1) 95,600 23,095,300 19 2,217 19 2,361 (Note 1) Increase due to the exercise of stock acquisition rights.」
The number of shares issued increased by 95,600 during the consolidated fiscal year through the exercise of stock acquisition rights, and the number of shares that could result in dilution continued to increase. - FY2025-H1WorsenedAnnual report
「1 April 2024–30 September 2024 (Note 1) 20,000 23,019,700 3 2,202 3 2,346 (Note 1) Increase due to the exercise of stock acquisition rights.」
The number of shares issued increased by 20,000 during the current interim consolidated accounting period through the exercise of stock acquisition rights, and the number of shares that could result in dilution continued to increase. The necessary risk quantification has been performed, but no accounting losses or other items indicating the actual occurrence of the risk have been disclosed. - FY2024WorsenedAnnual report
「1 April 2023–31 March 2024 (Notes 1 and 2) 55,600 22,999,700 11 2,198 △17 2,342 (Note 1) Increase due to the exercise of stock acquisition rights.」
The number of shares increased by 55,600 during the consolidated fiscal year through the exercise of stock acquisition rights. An additional 16,000 shares were issued by the filing date, and the number of shares that could result in dilution continued to increase. - FY2024-Q3WorsenedAnnual report
「1 October 2023–31 December 2023 (Note 1) 4,000 22,948,100 0 2,187 0 2,332 (Note 1) Increase due to the exercise of stock acquisition rights.」
The number of shares increased by 4,000 during the third-quarter accounting period through the exercise of stock acquisition rights, followed by an increase of 5,600 shares in January 2024 before the filing date. The number of shares that could result in dilution continued to increase. - FY2023-Q3WorsenedAnnual report
「1 October 2022–31 December 2022 (Note 1) 3,600 22,883,700 0 2,175 0 2,348 (Note 1) Increase due to the exercise of stock acquisition rights.」
The number of shares issued increased by 3,600 during the third-quarter accounting period through the exercise of stock acquisition rights, and the number of shares that could result in dilution of shareholder value continued to increase. - FY2023-Q2WorsenedAnnual report
「1 July 2022–30 September 2022 (Note) 12,400 22,880,100 5 2,174 5 2,347 (Note) Increase due to the exercise of stock acquisition rights.」
The number of shares issued increased by 12,400 during the second-quarter accounting period through the exercise of stock acquisition rights, and the number of shares that could result in dilution of shareholder value continued to increase. - FY2023-Q1WorsenedAnnual report
「1 April 2022–30 June 2022 (Note) 15,500 22,867,700 5 2,169 5 2,342 (Note) Increase due to the exercise of stock acquisition rights.」
The number of shares increased by 15,500 in the first quarter through the exercise of stock acquisition rights, and the number of shares that could result in dilution continued to increase. - FY2022-Q3WorsenedAnnual report
「1 October 2021–31 December 2021 (Note) 14,000 22,651,000 2 2,114 2 2,288 (Note) Increase due to the exercise of stock acquisition rights.」
The number of shares increased by 14,000 during the third-quarter accounting period through the exercise of stock acquisition rights, and the number of shares that could result in dilution continued to increase. - FY2022-Q2WorsenedAnnual report
「1 July 2021–30 September 2021 (Note 1) 44,500 22,637,000 12 2,111 12 2,285 (Note 1) Increase due to the exercise of stock acquisition rights.」
The number of shares increased by 44,500 during the second-quarter accounting period through the exercise of stock acquisition rights, and the number of shares that could result in dilution continued to increase. - FY2022-Q1WorsenedAnnual report
「(Note 1) Increase due to the exercise of stock acquisition rights.」
The number of shares increased by 38,000 through the exercise of stock acquisition rights between April and June 2021, with an additional increase of 17,000 shares by the filing date. The number of shares that could result in dilution continued to increase. - FY2021WorsenedAnnual report
「During the consolidated fiscal year, 233,100 shares were exercised」
The increase in shares issued through the exercise of stock acquisition rights continued in FY2021, with an increase of 233,100 shares during the year. - FY2021-Q3WorsenedAnnual report
「1 October 2020–31 December 2020 (Note 1) 193,700 22,515,100 48 2,081 48 2,254 (Note 1) Increase due to the exercise of stock acquisition rights.」
The number of shares increased by 193,700 during the third-quarter accounting period through the exercise of stock acquisition rights, increasing the total number of shares issued, share capital and capital reserves. The number of shares that could result in dilution continued to increase. - FY2020-Q3WorsenedAnnual report
「The increase resulted from the exercise of stock acquisition rights.」
The number of shares increased by 48,600 through the exercise of stock acquisition rights between October and December 2019, followed by an increase of 12,800 shares in January 2020. The number of shares that could result in dilution continued to increase. - FY2020-Q2WorsenedAnnual report
「1 July 2019–30 September 2019 (Note 1) 800 22,256,000 0 2,020 0 2,193」
The number of shares increased by 800 in the second quarter through the exercise of stock acquisition rights. It also increased by 38,600 between 1 October 2019 and 31 October 2019, and the number of shares that could result in dilution continued to increase. - FY2020-Q1WorsenedAnnual report
「1 April 2019–30 June 2019: 12,800 shares」
The number of shares increased by 12,800 in the first quarter through the exercise of stock acquisition rights, and an additional increase of 800 shares had also been disclosed by the filing date. The number of shares that could result in dilution continued to increase. - FY2019-Q3WorsenedAnnual report
「1 October 2018–31 December 2018: 44,400 shares / Increase due to the exercise of stock acquisition rights.」
During the current third-quarter accounting period, the number of shares increased by 44,400 through the exercise of stock acquisition rights. The number also increased by 800 shares by the filing date, and the number of shares that could result in dilution continued to increase. - FY2019-Q2WorsenedAnnual report
「1 July 2018–30 September 2018: 28,400 shares / Increase due to the exercise of stock acquisition rights.」
During the current second quarter, 28,400 shares were issued through the exercise of stock acquisition rights, and an increase of 10,000 shares had also been disclosed by the filing date. The number of shares that could result in dilution continued to increase. - FY2019-Q1WorsenedAnnual report
「1 April 2018–30 June 2018: 5,600 shares / Increase due to the exercise of stock acquisition rights.」
During the current first quarter, 5,600 shares were issued through the exercise of stock acquisition rights, and the number of shares that could result in dilution continued to increase. An additional increase of 25,600 shares was also disclosed in July. - FY2018WorsenedAnnual report
「The increase of 3,058,400 in the total number of common shares issued was entirely attributable to the exercise of stock acquisition rights.」
The exercise of stock acquisition rights resulted in the issuance of 3,058,400 shares, causing additional dilution. At period-end, 1,595,700 underlying shares remained under the third, fourth, sixth and seventh series of stock acquisition rights. - FY2018-Q3WorsenedAnnual report
「During the current nine-month consolidated accounting period, the Company issued new shares and disposed of treasury shares through the exercise of stock acquisition rights, increasing share capital by ¥1,369 million and capital surplus by ¥1,628 million, while treasury shares decreased by ¥314 million.」
The exercise of stock acquisition rights continued, and the total number of shares issued increased by 124,600 between October and December 2017. The risk of dilution became additionally apparent. - FY2018-Q2WorsenedAnnual report
「Change in total number of shares issued: 1,530,900 shares」
The number of shares increased by 1,530,900 through the exercise of stock acquisition rights between 1 July 2017 and 30 September 2017. The risk of dilution of existing shareholders' value and voting rights has become additionally apparent. - FY2018-Q1MaterialisedAnnual report
「Some of the fifth series of stock acquisition rights were exercised between 1 July 2017 and 4 August 2017. An overview of the exercise is provided below.」
The partial exercise of the fifth series of stock acquisition rights resulted in a payment of ¥648 million, the issuance of 717,200 new shares, and the disposal of 22,500 treasury shares. The risk of dilution of shareholder value from the exercise of stock acquisition rights materialized. - FY2017WorsenedAnnual report
「As of the end of May 2017, the number of potential shares represented by these stock acquisition rights was 3,415,600, equivalent to 17.92% of the total number of shares issued, 19,065,600.」
The proportion of potential shares rose from the previously disclosed 5.32% to 17.92%, increasing the potential dilution of shareholder value and voting rights. - FY2017-Q2WorsenedAnnual report
「Stock options approved by the Board of Directors on 20 July 2016: common shares, 59,200 (592 stock acquisition rights)」
During the current second quarter accounting period, 592 stock acquisition rights, representing 59,200 underlying common shares, were issued, adding potential shares that could result in dilution of shareholder value. - FY2016First statedAnnual report
「As of the end of May 2016, the number of potential shares represented by these stock acquisition rights was 506,800, equivalent to 5.32% of the total number of shares issued, 9,532,800.」
The potential dilution of existing shareholders' value and voting rights from the exercise of stock options granted to directors, officers and employees was disclosed.